These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 25029569

  • 1. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 2. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY.
    Cochrane Database Syst Rev; 2014 Oct 23; 2014(10):CD007744. PubMed ID: 25340915
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO, Sebba AI, Rubin BR, Ruoff GE, Kremer J, Bird S, Smugar SS, Fitzgerald BJ, O'Brien K, Tershakovec AM.
    Rheumatology (Oxford); 2007 Mar 23; 46(3):496-507. PubMed ID: 16936327
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 23; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 5. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC, Chu KM, Hui WM, Wong BC, Hu WH, Wong WM, Chan AO, Wong J, Lam SK.
    Am J Med; 2005 Nov 23; 118(11):1271-8. PubMed ID: 16271912
    [Abstract] [Full Text] [Related]

  • 6. Incidence and possible risk factors for clinical upper gastrointestinal events in patients taking selective cyclooxygenase-2 inhibitors: A prospective, observational, cohort study in Taiwan.
    Hsiang KW, Chen TS, Lin HY, Luo JC, Lu CL, Lin HC, Lee KC, Chang FY, Lee SD.
    Clin Ther; 2010 Jul 23; 32(7):1294-303. PubMed ID: 20678677
    [Abstract] [Full Text] [Related]

  • 7. Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
    Kristensen LE, Jakobsen AK, Askling J, Nilsson F, Jacobsson LT.
    Arthritis Care Res (Hoboken); 2015 Aug 23; 67(8):1137-49. PubMed ID: 25623277
    [Abstract] [Full Text] [Related]

  • 8. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
    Motsko SP, Rascati KL, Busti AJ, Wilson JP, Barner JC, Lawson KA, Worchel J.
    Drug Saf; 2006 Aug 23; 29(7):621-32. PubMed ID: 16808554
    [Abstract] [Full Text] [Related]

  • 9. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 23; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 10. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.
    Andersohn F, Schade R, Suissa S, Garbe E.
    Stroke; 2006 Jul 23; 37(7):1725-30. PubMed ID: 16728684
    [Abstract] [Full Text] [Related]

  • 11. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators.
    Am J Med; 2006 Mar 23; 119(3):255-66. PubMed ID: 16490472
    [Abstract] [Full Text] [Related]

  • 12. Risk of cardiovascular events associated with selective COX-2 inhibitors.
    Mukherjee D, Nissen SE, Topol EJ.
    JAMA; 2006 Mar 23; 286(8):954-9. PubMed ID: 11509060
    [Abstract] [Full Text] [Related]

  • 13. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
    Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL.
    Ann Intern Med; 2005 Feb 01; 142(3):157-64. PubMed ID: 15684203
    [Abstract] [Full Text] [Related]

  • 14. Factors associated with celecoxib and rofecoxib utilization.
    Rawson NS, Nourjah P, Grosser SC, Graham DJ.
    Ann Pharmacother; 2005 Apr 01; 39(4):597-602. PubMed ID: 15755796
    [Abstract] [Full Text] [Related]

  • 15. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2005 Apr 01; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 16. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.
    Lancet; 2005 Apr 01; 364(9450):2021-9. PubMed ID: 15582059
    [Abstract] [Full Text] [Related]

  • 17. Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Elliott WJ.
    Curr Hypertens Rep; 2010 Aug 01; 12(4):258-66. PubMed ID: 20524091
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S.
    Arthritis Rheum; 2006 May 01; 54(5):1378-89. PubMed ID: 16645966
    [Abstract] [Full Text] [Related]

  • 19. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C.
    BMJ; 2006 Jun 03; 332(7553):1302-8. PubMed ID: 16740558
    [Abstract] [Full Text] [Related]

  • 20. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
    McCormack PL.
    Drugs; 2011 Dec 24; 71(18):2457-89. PubMed ID: 22141388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.